Use of IL-22 for the treatment of conditions of metabolic disorders
The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.
1. A method of reducing adipocyte size in an overweight mammal, comprising administering to said mammal a composition, said composition comprising a therapeutically effective amount of a polypeptide consisting essentially of IL-22 and reducing adipocyte size in said mammal.
2. The method of claim 1 , wherein said polypeptide consists of isolated, purified IL-22.
3. The method of claim 1 , wherein said adipocyte size is associated with or caused by metabolic disorder.
4. The method of claim 3 , wherein said metabolic disorders comprises acquired or hereditary obesity.
5. The method of claim 1 , wherein said polypeptide is recombinantly synthesized.
6. The method of claim 1 , wherein said polypeptide consisting essentially of human IL-22 or mouse IL-22.